Effective influenza vaccines for children: A critical unmet medical need and a public health priority

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 3, 2012, Pages 389-393

  Banzhoff, Angelika ^a   Stoddard, Jeffrey J ^b  

^a GSK Marburg Vaccines and Diagnostics   (Germany)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

Author keywords

Children; Immunogenicity; Influenza vaccine; MF59 adjuvant

Indexed keywords

INFLUENZA VACCINE; MIFAMURTIDE; FLUAD VACCINE; VACCINE;

ADJUVANT THERAPY; COST OF ILLNESS; DRUG EFFICACY; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HEALTH CARE NEED; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INCIDENCE; INFLUENZA VACCINATION; INJECTION SITE REACTION; INJECTION SITE SWELLING; NOTE; POLYMERASE CHAIN REACTION; PREVENTION AND CONTROL; PUBLIC HEALTH SERVICE; RECOMMENDED DRUG DOSE; RISK BENEFIT ANALYSIS; SEASONAL INFLUENZA; SEROCONVERSION; SYSTEMIC DISEASE; ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL (TOPIC); FEMALE; IMMUNOLOGY; INFANT; INFLUENZA; MALE; NEWBORN; PRESCHOOL CHILD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA, HUMAN; MALE; VACCINES;

EID: 84874423201     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.8.3.18561     Document Type: Note

References (37)

1. Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2008; CD004879; PMID:18425905
2. Centers for Disease Control and Prevention (CDC). Influenza-associated pediatric deaths - United States, September 2010-August 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1233-8; PMID:21918492
3. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25:5086-96; PMID:17544181; http://dx.doi.org/10.1016/j.vaccine.2007.03.046
4. Paget WJ, Balderston C, Casas I, Donker G, Edelman L, Fleming D, et al & EPIA collaborators. Assessing the burden of paediatric influenza in Europe: the European Paediatric Influenza Analysis (EPIA) project. Eur J Pediatr 2010; 169:997-1008; PMID:20229049; http://dx.doi.org/10.1007/s00431-010-1164-0
5. Nicholson KG, McNally T, Silverman M, Simons P, Stockton JD, Zambon MC. Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children. Vaccine 2006; 24:102-8; PMID:16310899; http://dx.doi.org/10.1016/j.vaccine.2005.02.004
6. Sachedina N, Donaldson LJ. Paediatric mortality related to pandemic influenza A H1N1 infection in England: an observational population-based study. Lancet 2010; 376:1846-52; PMID:21030071; http://dx.doi.org/10.1016/S0140- 6736(10)61195-6
7. Fuhrman C, Bonmarin I, Paty AC, Duport N, Chiron E, Lucas E, et al. Severe hospitalised 2009 pandemic influenza A(H1N1) cases in France, 1 July-15 November 2009. Euro Surveill 2010; 15:19463; PMID:20085690
8. Forster J, Ihorst G, Rieger CH, Stephan V, Frank HD, Gurth H, et al. Prospective population-based study of viral lower respiratory tract infections in children under 3 years of age (the PRI.DE study). Eur J Pediatr 2004; 163:709-16; PMID:15372233; http://dx.doi.org/10.1007/s00431-004-1523-9
9. Federal Health Monitoring. Deaths per 100,000 inhabitants for influenza. 2010b. Available at: http://www.gbe-bund.de/oowa921-install/servlet/oowa/aw92/ dboowasys921.xwdevkit/xwd_init?gbe.isgbetol/xs_start_neu/&p_aid=3&p_aid= 60849577&nummer=5&p_sprache=E&p_indsp=133&p_aid=97378324 [Accessed July 22, 2011].
10. Calitri C, Gabiano C, Garazzino S, Pinon M, Zoppo M, Cuozzo M, et al. Clinical features of hospitalised children with 2009 H1N1 influenza virus infection. Eur J Pediatr 2010; 169:1511-5; PMID:20652313; http://dx.doi.org/10. 1007/s00431-010-1255-y
11. van 't Klooster TM, Wielders CC, Donker T, Isken L, Meijer A, van den Wijngaard CC, et al. Surveillance of hospitalizations for 2009 pandemic influenza A(H1N1) in the Netherlands, 5 June-31 December 2009. Euro Surveillance 2010;15:19461.
12. Montes M, Vicente D, Pérez-Yarza EG, Cilla G, Pérez- Trallero E. Influenza-related hospitalisations among children aged less than 5 years old in the Basque Country, Spain: a 3-year study (July 2001-June 2004). Vaccine 2005; 23:4302-6; PMID:16005741; http://dx.doi.org/10.1016/j.vaccine. 2005.04.006
13. León Gómez I, Flores Segovia VM, Jiménez Jorge S, Larrauri Cámara A, Palmera Suárez R, Simón Soria F. [Excess mortality in Spain during transmission of pandemic influenza in 2009]. [in Spanish]. Rev Esp Salud Publica 2010; 84:589-96; PMID:21203721
14. Heikkinen T, Silvennoinen H, Peltola V, Ziegler T, Vainionpaa R, Vuorinen T, et al. Burden of influenza in children in the community. J Infect Dis 2004; 190:1369-73; PMID:15378427; http://dx.doi.org/10.1086/424527
15. Silvennoinen H, Peltola V, Vainionpää R, Ruuskanen O, Heikkinen T. Incidence of influenza-related hospitalizations in different age groups of children in Finland: a 16-year study. Pediatr Infect Dis J 2011; 30:e24-8; PMID:21298851; http://dx.doi.org/10.1097/INF.0b013e3181fe37c8
16. Robert-Koch-Institut. Abschlussbericht der Influenzasaison 2008/09. Available at: http://influenza.rki.de/Saisonberichte/2008.pdf [Accessed July 25, 2011].
17. Robert-Koch-Institut. Bericht zur Epidemiologie der Influenza in Deutschland Saison 2009/10. Available from: http://influenza.rki.de/ Saisonberichte/2009.pdf [Accessed July 25, 2011].
18. Mustaquim D, Bishop A, Epperson S, Kniss K, Blanton L, Dhara R, et al & Centers for Disease Control and Prevention (CDC). Update: influenza activity - United States, 2009-10 season. MMWR Morb Mortal Wkly Rep 2010; 59:901-8; PMID:20671661
19. Fairbrother G, Cassedy A, Ortega-Sanchez IR, Szilagyi PG, Edwards KM, Molinari NA, et al & New Vaccine Surveillance Network (NVSN). High costs of influenza: Direct medical costs of influenza disease in young children. Vaccine 2010; 28:4913-9; PMID:20576536; http://dx.doi.org/10.1016/j.vaccine.2010.05.036
20. Hassan F, Lewis TC, Davis MM, Gebremariam A, Dombkowski K. Hospital utilization and costs among children with influenza, 2003. Am J Prev Med 2009; 36:292-6; PMID:19201147; http://dx.doi.org/10.1016/j.amepre.2008.11.016
21. Federal Health Monitoring. Diseases/health problems. Infections. Influenza. 2010a. Available at: http://www.gbe-bund.de/gbe10/trecherche. prc_them_rech?tk=8500 &tk2=13400&p_uid=gast&p_aid= 63460257&p_sprache=E&cnt_ut=20&ut=13520 [Accessed July 22, 2011].
22. Ehlken B, Ihorst G, Lippert B, Rohwedder A, Petersen G, Schumacher M, et al & PRIDE Study Group. Economic impact of community-acquired and nosocomial lower respiratory tract infections in young children in Germany. Eur J Pediatr 2005; 164:607-15; PMID: 15965766; http://dx.doi.org/10.1007/s00431-005-1705-0
23. Meier CR, Napalkov PN, Wegmüller Y, Jefferson T, Jick H. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis 2000; 19:834-42; PMID:11152308; http://dx.doi.org/10.1007/ s100960000376
24. Belongia EA, Irving SA, Waring SC, Coleman LA, Meece JK, Vandermause M, et al. Clinical characteristics and 30-day outcomes for influenza A 2009 (H1N1), 2008-2009 (H1N1), and 2007-2008 (H3N2) infections. JAMA 2010; 304:1091-8; PMID: 20823435; http://dx.doi.org/10.1001/jama.2010.1277
25. Prosser LA, Bridges CB, Uyeki TM, Hinrichsen VL, Meltzer MI, Molinari NA, et al. Health benefits, risks, and cost-effectiveness of influenza vaccination of children. Emerg Infect Dis 2006; 12:1548-58; PMID:17176570; http://dx.doi.org/10.3201/eid1210.051015
26. Tappenden P, Jackson R, Cooper K, Rees A, Simpson E, Read R, et al. Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation. Health Technol Assess 2009; 13:iii-, ix-xii, 1-246; PMID:19215705
27. Principi N, Esposito S, Marchisio P, Gasparini R, Crovari P. Socioeconomic impact of influenza on healthy children and their families. Pediatr Infect Dis J 2003; 22(Suppl):S207-10; PMID:14551476; http://dx.doi.org/10.1097/01.inf.0000092188.48726.e4
28. Bhattarai A, Villanueva J, Palekar RS, Fagan R, Sessions W, Winter J, et al & Pennsylvania Working Group. Viral shedding duration of pandemic influenza A H1N1 virus during an elementary school outbreak - Pennsylvania, May-June 2009. Clin Infect Dis 2011; 52(Suppl 1):S102-8; PMID:21342880; http://dx.doi.org/10.1093/cid/ciq026
29. Lewin EB. A paradigm for the control of influenza. J Infect Dis 2010; 202:1619-22; PMID:21028956; http://dx.doi.org/10.1086/657090
30. Jaspan HB, Lawn SD, Safrit JT, Bekker LG. The maturing immune system: implications for development and testing HIV-1 vaccines for children and adolescents. AIDS 2006; 20:483-94; PMID:16470112; http://dx.doi.org/10.1097/01. aids.0000210602.40267.60
31. Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 2003; 49:177-84; PMID:12679609; http://dx.doi.org/10.1159/000069172
32. Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 2009; 27:6959-65; PMID:19751689; http://dx.doi.org/10.1016/j.vaccine.2009.08.101
33. Tsai TF, Crucitti A, Nacci P, Nicolay U, Della Cioppa G, Ferguson J, et al. Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy. Scand J Infect Dis 2011; 43:702-6; PMID:21534891; http://dx.doi.org/10.309/ 00365548.2011.580777
34. Iannazzo S. Pharmacoeconomic evaluation of the MF59-adjuvanted influenza vaccine in the elderly population in Italy. J Prev Med Hyg 2011; 52:1-8; PMID:21710816
35. Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009; 28:563-71; PMID:19561422; http://dx.doi.org/10.1097/INF.0b013e31819d6394
36. Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 2009; 27:6291-5; PMID:19840662; http://dx.doi.org/10.1016/j.vaccine.2009.02.004
37. Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt H-J, et al. Efficacy of an MF59®-adjuvanted seasonal influenza vaccine versus non-adjuvanted influenza vaccine and control vaccine in 6-<72 month old children. N Engl J Med 2011; Oct 13; 365(15):1406-16; PMID:21995388